PPY and neuroendocrine neoplasm: Current international MEN1 guidelines recommend annual biomarker screening of patients with MEN1, including chromogranin A (CgA) and pancreatic polypeptide (PP) screenings for diagnosis and follow-up of patients with gastroenteropancreatic neuroendocrine neoplasms (NENs) [3].